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ABSTRACT
Introduction: Methicillin-resistant Staphylococ-
cus aureus (MRSA) bacteremia confers consider-
able morbidity and mortality. Although
vancomycin or daptomycin monotherapy is
usually curative, prolonged bacteremia necessi-
tating supplemental ceftaroline has occurred.
The practice has led to the question of whether
to continue with ceftaroline following bac-
teremia resolution.
Methods: Adult patients hospitalized with
MRSA bacteremia at the University of Kentucky
Medical Center between January 2015 and
December 2017 were retrospectively reviewed.
Study subjects required supplemental ceftaro-
line due to 4 or more days of bacteremia despite
vancomycin or daptomycin. They additionally
had accompanying native valve infective
endocarditis, osteomyelitis, or brain abscess.
Patients were divided into two cohorts. One
group continued with ceftaroline plus van-
comycin or daptomycin following bacteremia
resolution (combination therapy group). The
other group received vancomycin or dapto-
mycin alone (monotherapy group). All involved
received 6–8 weeks of therapy. Patients’ Pitt
bacteremia score (PBS) and Charlson comor-
bidity index (CCI) values were calculated.
Treatment outcomes of inpatient mortality,
recurrence of bacteremia, 30-day readmission,
acute kidney injury, and leukopenia were
recorded and compared.
Results: A total of 30 patients comprised the
study population. 15 patients were assigned to
each cohort. The median PBS value of the
combination therapy group was 2, compared
with 1 among the monotherapy group. The
median CCI score of both groups was 0. No
statistically significant difference in the afore-
mentioned treatment outcomes was seen
between the two groups.
Conclusion: In subjects with complicated and
prolonged MRSA bacteremia requiring supple-
mental ceftaroline, clinical outcomes did not
differ among patients prescribed vancomycin or
daptomycin alone following bacteremia resolu-
tion versus patients who continued combina-
tion therapy.
Keywords: Bacteremia; Ceftaroline; Dapto-
mycin; MRSA; Vancomycin
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Key Summary Points
Why carry out this study?
Supplemental ceftaroline is an established
option in the treatment of prolonged
MRSA bacteremia refractory to
vancomycin or daptomycin therapy.
The question of whether to continue with
ceftaroline plus vancomycin or
daptomycin following bacteremia
resolution, however, remains unanswered.
In hopes of uncovering findings
supporting a particular regimen,
treatment outcomes were compared in
patients prescribed vancomycin or
daptomycin alone following bacteremia
resolution versus patients who continued
combination therapy.
What was learned from the study?
No statistically significant difference in
inpatient mortality, recurrence of
bacteremia, 30-day readmission, acute
kidney injury, or leukopenia was seen in
patients prescribed vancomycin or
daptomycin alone following bacteremia
resolution versus patients who continued
combination therapy.
Considering treatment outcomes did not
differ in patients prescribed vancomycin
or daptomycin alone following
bacteremia resolution, our finding




(MRSA) bacteremia is a formidable disease
associated with considerable morbidity and
mortality [1, 2]. Vancomycin or daptomycin has
traditionally been the mainstay of therapy for
invasive MRSA infection. However, treatment
failures have happened in recent years, as
defined by persistent bacteremia, bacteremia
recurrence post-antimicrobial cessation, and/or
death 30 days post-treatment [3]. Vancomycin’s
slow bactericidal activity, as well as the devel-
opment of increased glycopeptide tolerance in
MRSA isolates administered vancomycin, have
been blamed for these occurrences [4, 5]. The
latter issue has also plagued daptomycin, with
nonsusceptible isolates emerging during treat-
ment being implicated in poor clinical out-
comes [6].
In 2010, the Food and Drug Administration
(FDA) approved the use of ceftaroline for the
treatment of acute bacterial skin and skin-
structure infections (ABSSSI) caused by MRSA.
The antibiotic later received additional approval
for the solitary treatment of ABSSSI-associated
bacteremia [7]. Ceftaroline’s value in treating
MRSA bacteremia secondary to non-ABSSSI
causes such as infective endocarditis and
osteomyelitis [8, 9] led to its investigational use
as a salvage measure for vancomycin- or dap-
tomycin-refractory MRSA bacteremia [9, 10].
Findings of bacteremia resolution plus in vitro
evidence of antibiotic synergy [11, 12] moti-
vated others to follow suit. Nowadays, it is
common practice to add ceftaroline to patients
with persistent bacteremia despite vancomycin
or daptomycin.
The effectiveness of supplemental ceftaroline
in treating refractory MRSA bacteremia is well
established. However, the question of whether
to continue with ceftaroline following bac-
teremia resolution remains unanswered. With
this in mind, we studied adults with compli-
cated and prolonged MRSA bacteremia pre-
scribed ceftaroline plus vancomycin or
daptomycin. We specifically compared treat-
ment outcomes in those who continued with
combination therapy following bacteremia res-
olution versus vancomycin or daptomycin
alone in the hope of uncovering findings sup-
porting a particular regimen.
METHODS
Study Design and Subject Selection
Adult patients (aged 21–99 years) hospitalized
between January 1, 2015 and December 31,
78 Infect Dis Ther (2020) 9:77–87
2017 at the University of Kentucky Medical
Center with monomicrobial MRSA bacteremia
were retrospectively identified. Subjects with
bacteremia lasting 4 days or longer secondary to
deep-seated infection i.e., native valve infective
endocarditis (IE), osteomyelitis, and/or brain
abscess underwent further analysis. Of these,
only those who received supplemental ceftaro-
line following 4 or more days of bacteremia
despite vancomycin or daptomycin were stud-
ied. Pregnant individuals, patients allergic to
ceftaroline, and patients who were discharged
against medical advice or had care withdrawn
during their hospitalization, were excluded. Of
note, none of the study subjects received
antibiotics aside from vancomycin, dapto-
mycin, or ceftaroline for more than 72 h fol-
lowing the detection of MRSA in blood culture
specimens.
Included patients were separated into two
treatment groups. One cohort comprised sub-
jects who continued on ceftaroline plus either
vancomycin or daptomycin following bac-
teremia resolution (combination therapy
group). The other cohort (monotherapy group)
comprised subjects who received vancomycin
or daptomycin alone following bacteremia res-
olution, with ceftaroline being discontinued no
later than 24 h after the first finalized negative
blood culture set. All patients received 6–-
8 weeks of antimicrobial(s) upon bacteremia
resolution due to their underlying infections.
Age, sex, comorbid conditions, length of
MRSA bacteremia, and duration of antibiotics,
as well as serum creatinine and white blood cell
count results of subjects, were documented.
Instances of death or bacteremia recurrence
while hospitalized, along with instances of
30-day readmission, were recorded. Vital signs,
need for intravenous vasopressor agents, need
for mechanical ventilation, incidences of car-
diac arrest, and patient mentation according to
electronic medical record (EMR) documentation
were noted the day of positive blood cultures.
The presented study received approval from
the University of Kentucky Office of Research
Integrity Institutional Review Board and con-
formed with the Helsinki Declaration of 1964
(as revised in 2013) concerning human and
animal rights. On account of the investigation
being carried out through retrospective review
of medical records, ethics approval was not
required due to no foreseeable impact on the
rights and/or welfare of the subjects involved.
Consent from study participants was addition-
ally not obtained due to the study involving
retrospective review of medical records.
Antimicrobial Susceptibility Testing
Two discrete methods of antimicrobial suscep-
tibility testing identified MRSA isolates in the
study. This was due to a procedural change
midway through the trial period. Antimicrobial
gradient diffusion testing, i.e., bioMérieux
EtestTM, was employed between January 1, 2015
and March 31, 2016. During this time, S. aureus
strains with a minimum inhibitory concentra-
tion (MIC) C 4 lg/mL to oxacillin were classi-
fied as MRSA per Clinical and Laboratory
Standards Institute (CLSI) criteria [13]. The BD
PhoenixTM Automated Microbiology System
was adopted thereafter. S. aureus strains identi-
fied as resistant to cefoxitin (defined by an
MIC C 8 lg/mL) underwent corroborative disk
diffusion testing. Those exhibiting an inhibi-
tion zone diameter B 21 mm to cefoxitin were
thereafter classified as MRSA per CLSI criteria
[13].
Vancomycin and daptomycin susceptibility
testing were also performed using EtestTM and
PhoenixTM methods, in line with the time
intervals previously mentioned. MRSA isolates
with a MIC B 2 lg/mL to vancomycin were
deemed vancomycin-susceptible, and those
with an MIC B 1 lg/mL to daptomycin were
deemed daptomycin-susceptible. The desig-
nated breakpoints were shared by both EtestTM
and PhoenixTM. This aside, ceftaroline suscep-
tibility testing was accomplished entirely by
means of EtestTM. MRSA isolates having an
MIC B 1 lg/mL to ceftaroline were labeled cef-
taroline-susceptible.
No MRSA isolates in the study demonstrated
daptomycin or ceftaroline resistance. Two iso-
lates belonging to the combination therapy
group developed borderline vancomycin sus-
ceptibility (MIC = 2 lg/mL) in the midst of
vancomycin therapy, i.e., MIC creep. The
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instances occurred while EtestTM was employed.
However, no MRSA isolates were vancomycin-
intermediate or vancomycin-resistant according
to CLSI definitions [13].
Clinical Data Collection and Definitions
Subjects with MRSA bacteremia were identified
via institutional blood culture data. Episodes of
native valve IE, osteomyelitis, or brain abscess
were identified via chart review. Cases of native
valve IE were validated provided they met Infec-
tious Diseases Society of America (IDSA)-endorsed
modified Duke criteria [14]. Instances of
osteomyelitis or brain abscess were validated if
diagnosed intraoperatively, or had compatible
computed tomography/magnetic resonance
imaging findings. Acute kidney injury (AKI) was
diagnosed per standardized risk, injury, failure,
loss of kidney function, and end-stage kidney
disease criteria in patients without pre-existing
end-stage renal disease. However, logistical con-
straints led to only serum creatinine determinants
being utilized. In keeping with standardized lab-
oratory parameters, leukopenia was characterized
by a serum white blood cell count below 3.7 k/lL.
At least two consecutive eligible creatinine or
white blood cell count values over a minimum
span of 24 h were required for the respective
diagnoses of AKI or leukopenia. This was to lessen
the possibility of laboratory error.
Charlson comorbidity index (CCI) and Pitt
bacteremia score (PBS) values were calculated
using conventional scoring methods. Relevant
medical conditions detailed in EMR documen-
tation determined individual CCI values [15].
PBS values incorporated patient clinical status,
medical needs, and documented vital signs
within 24 h of bacteremia detection. The high-
est computed amount was ultimately selected
for analysis [16].
Antimicrobial Dosing
Parenteral vancomycin was empirically dosed at
15–20 mg/kg every 8–12 h. The specific regimen
was dependent upon individual renal function.
Dosing was thereafter adjusted to attain IDSA-
recommended trough levels of 15–20 lg/mL
[17]. Daptomycin was dosed at 8–10 mg/kg
once daily. This high-dose regimen was chosen
over conventional 6 mg/kg daily dosing due to a
reduced risk of antimicrobial resistance and the
potential for accelerated bacterial clearance
[18, 19]. Subjects with a creatinine clearance
(CrCl) above 50 mL/min were prescribed
600 mg of intravenous ceftaroline every 8–12 h.
Patients otherwise were dosed based on their
calculated CrCl in accordance with FDA rec-
ommendations [20].
Statistical Analysis
Data were analyzed using SAS v.9.4 (Cary, NC,
USA). p values \0.05 were regarded as statisti-
cally significant. Descriptive statistics were cal-
culated with means, standard deviations,
medians, and interquartile ranges for all con-
tinuous variables; frequencies and percentages
for all categorical variables. To examine bivari-
ate associations with drug type, v2 tests and
Fisher’s Exact tests were conducted for categor-
ical variables, and t tests and Mann–Whitney
U tests were conducted for continuous variables.
Inverse probability of treatment weighting
(IPTW) was utilized to reduce potential bias and
confounding by indication. Patient propensity
scores were derived via logistic regression and




During the study period, we identified 263
patients with MRSA bacteremia lasting 4 days or
longer. All were prescribed either vancomycin
or daptomycin. One hundred twenty-three of
these patients were later prescribed supple-
mental ceftaroline. Seven patients, however,
were removed from study consideration due to
ceftaroline being started within 3 days of bac-
teremia onset.
Twenty-eight of the remaining patients were
excluded due to the absence of underlying
native valve IE, osteomyelitis, or brain abscess.
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Three patients were additionally excluded due
to care being withdrawn during their hospital
stay. Finally, 5 patients were excluded due to
leaving against medical advice. In the end, 80
subjects constituted our preliminary investiga-
tional population.
Fifty patients were later removed from the
study. Specifically, 8 patients were excluded due
to dying prior to bacteremia resolution. Twenty-
five patients were additionally excluded due to
being interhospital transfers with pre-existing
MRSA bacteremia—thereby preventing requisite
PBS value calculation. Finally, 17 patients were
excluded due to being prescribed discordant
antimicrobial regimens following bacteremia
resolution. This resulted in a final study popu-
lation of 30 subjects (Fig. 1).
Monotherapy Group Patient
Characteristics and Outcomes
Fifteen patients (8 males, 7 females) comprised
the monotherapy cohort. Ages ranged from 25
to 70 years old, with an average age of 41.
Thirteen subjects had native valve IE (87%), 1
subject had osteomyelitis (7%), and 1 subject
was diagnosed with both conditions (7%). Two
of the 12 patients (17%) with native valve IE
warranting early valve surgery [14] underwent
valve replacement while bacteremic. Ceftaro-
line was begun within 4 to 11 days of refractory
bacteremia, with a median value of 6 days.
Bacteremia duration varied between 4 and
11 days, with a median value of 7 days. PBS
values ranged from 0 to 6, corresponding to a
median value of 1. CCI scores were between 0
and 5, with a median score of 0 (Table 1).
Vancomycin was initially prescribed to all
subjects. Five patients, however, were later
changed to daptomycin. This was due to AKI in
3 patients. The other 2 patients were changed to
daptomycin on account of provider preference.
In terms of treatment duration, 2 patients
received 7 weeks of therapy and 12 subjects
received 6 weeks of therapy. This amounted to a
median value of 6 weeks.
There were no incidences of leukopenia in
the monotherapy group. Six patients were
diagnosed with AKI. None, however, required
hemodialysis at the time of discharge. Two
instances of 30-day readmission occurred,
though they were unrelated to patients’ previ-
ous hospitalizations. One was a result of poly-
merase chain reaction-confirmed human
metapneumovirus pneumonia. The other was
to prevent an interruption in outpatient par-
enteral antimicrobial therapy. One subject
encountered a brief 2-day period of bacteremia
recurrence prior to ceftaroline discontinuation.
It occurred as vancomycin was replaced with
daptomycin due to vancomycin-induced AKI.
This led to Ceftaroline being administered alone
for approximately 12 h. Considering the cir-
cumstances, the bacteremia recurrence seem-
ingly was provoked by treatment interruption
as opposed to deficient therapy.
One patient in the monotherapy group
expired. A 33-year-old female with native valve
IE, she had an abrupt decline status-post bio-
prosthetic mitral valve replacement (5 days after
bacteremia resolution). She was diagnosed with
obstructive shock secondary to a post-operative
pericardial thrombus. Despite undergoing
emergent mediastinal exploration with suc-
cessful evacuation of the clot, she ultimately
arrested. No autopsy was performed following
her death.
Combination Therapy Group Patient
Characteristics and Outcomes
Fifteen patients (10 males, 5 females) comprised
the combination therapy cohort. Ages ranged
from 24 to 73 years old, with an average age of
46. Seven subjects had osteomyelitis (47%), 5
subjects had native valve IE (33%), 2 subjects
were diagnosed with both conditions (13%),
and 1 person had a cerebral abscess (7%). One of
the 7 patients (14%) with native valve IE war-
ranting early valve surgery [14] underwent valve
replacement while bacteremic. Ceftaroline was
begun within 4 to 10 days of refractory bac-
teremia, with a median value of 6 days. Bac-
teremia duration varied between 5 and 14 days,
with a median value of 8 days. PBS values ran-
ged from 0 to 6, corresponding to a median
value of 2. CCI scores were between from 0 and
3, with a median score of 0 (Table 1).
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Vancomycin was initially prescribed to all
subjects. Twelve patients, however, were later
changed to daptomycin. This was due to the
emergence of borderline vancomycin-suscepti-
ble MRSA strains in 2 patients, AKI in one per-
son, an allergic reaction in one person, drug-
induced neutropenia in one person, and an
inability to attain a consistent vancomycin
trough of 15–20 ug/mL in one person. The
other 6 patients were changed to daptomycin
on account of provider preference. In terms of
treatment duration, 3 patients received 8 weeks
Fig. 1 Enrollment flow chart and inclusion/exclusion criteria
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of therapy and 9 patients received 6 weeks of
therapy. This amounted to a median value of
6 weeks.
There was an instance of leukopenia in
one person belonging to the combination ther-
apy group. A mild aberration, it led to no
particular intervention or detriment. Seven pa-
tients were diagnosed with AKI—2 of whom
required continued hemodialysis upon hospital
discharge. No instances of 30-day readmission
or bacteremia recurrence occurred.
Three patients in the combination therapy
group expired. The first subject was a 40-year-
old male with native valve IE who died 6 days
following bacteremia resolution. Suffering from
septic central nervous system emboli with






Age (years), mean (SD) 41 (13.6) 46 (15.9) 0.42
Sex, n (%) 0.71
Female 7 (47) 5 (33)
Male 8 (53) 10 (67)
Accompanying infections, n (%)
Osteomyelitis 1 (7) 7 (47) 0.04
Native valve IE 13 (87) 5 (33) 0.01
Osteomyelitis and native valve IE 1 (7) 2 (13) 0.99
Cerebral abscess 0 (0) 1 (7) 0.99
Surgical candidates who underwent valve
replacement, n (%)
2 (17) 1 (14) 0.99
PBS score, median (IQR) 1 (4.0) 2 (4.0) 0.61
CCI score, median (IQR) 0 (1.0) 0 (2.0) 0.85
Bacteremia duration preceding ceftaroline (days),
median (IQR)
6 (2.0) 6 (3.0) 0.85
Total bacteremia duration (days), median (IQR) 7 (3.0) 8 (4.0) 0.22
Treatment duration (weeks), median (IQR) 6 (0) 6 (1.5) 0.39
MRSA strains with MIC = 2 lg/mL 2 0 0.48
Clinical outcomes, n (%)
AKI 6 (40) 7 (47) 0.36
Leukopenia 0 (0) 1 (7) 0.35
Bacteremia recurrence 1 (7) 0 (0) 0.27
30-Day readmission 2 (13) 0 (0) 0.14
Death 1 (7) 3 (20) 0.24
AKI acute kidney injury, CCI Charlson comorbidity index, IE infective endocarditis, IQR interquartile range, MIC
minimum inhibitory concentration, MRSA methicillin-resistant Staphylococcus aureus, PBS Pitt bacteremia score, SD
standard deviation
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hemorrhagic manifestations (first detected
3 days after admission), he expired due to sub-
sequent uncal herniation. The second subject
was a 36-year-old female with native valve IE
who died 26 days following bacteremia resolu-
tion. She progressed well clinically up until
sudden hypoxemia led to the diagnosis of acute
pulmonary embolism with right heart strain.
Despite anticoagulation and aggressive life
support measures, she expired within 48 h. The
third subject was a 69-year-old male with both
native valve IE and osteomyelitis who died
23 days following bacteremia resolution. A few
days after his unrivaled 14-day duration of
bacteremia ended, acute hypoxemia led to the
discovery of aortic valve perforation via
echocardiography. He was deemed to not be a
surgical candidate by cardiothoracic surgery on
the account of clinical instability. He eventually
expired due to progressive cardiac decompen-
sation refractory to medical therapy. Of note,
none of the above patients underwent autopsy.
Group Outcome Comparisons
No statistically significant difference in patient
outcomes was seen after comparing the two
treatment groups following IPTW standardiza-
tion (Table 1). Bacteremia recurrence occurred in
1 person in the monotherapy group (7%) versus 0
in the combination therapy group (p = 0.27).
Two cases of 30-day readmission occurred in the
monotherapy group (13%) versus 0 in the com-
bination therapy group (p = 0.14). While 3
patients died in the combination therapy group
(20%) versus only 1 in the monotherapy group
(7%), the difference was not statistically signifi-
cant (p = 0.24). A total of 6 instances of AKI
occurred in the monotherapy group (40%) versus
7 in the combination therapy group (47%)
(p = 0.36). Finally, 1 episode of leukopenia
occurred in the monotherapy group (7%) versus
0 in the combination therapy group (p = 0.35).
DISCUSSION
To the best of our knowledge, this is the first
published study investigating whether to con-
tinue with ceftaroline following bacteremia
resolution in patients with prolonged MRSA
bacteremia requiring combination therapy. As
detailed previously, no statistically significant
difference in treatment outcomes was seen
between the combination therapy and
monotherapy groups. The result complements
an in vitro study reported by Barber [21] which
compared MRSA isolates treated with dapto-
mycin plus ceftaroline for 8 days to MRSA iso-
lates treated with daptomycin plus ceftaroline
for 4 days followed by a 4-day course of dapto-
mycin alone. Pharmacokinetic/pharmacody-
namic analysis found no significant difference
in growth inhibition between the two regimens.
Considering treatment outcomes did not
differ in patients prescribed vancomycin or
daptomycin alone following bacteremia resolu-
tion, our finding encourages confining ceftaro-
line use to active bacteremia. It relatedly affords
beneficial medical and financial repercussions.
Adverse effects of ceftaroline ranging from mild
intolerance, e.g., headache, nausea, diarrhea,
etc. to worrisome Clostridioides difficile infection
have been reported [22].Given this, requisite
employment seems prudent from a patient
safety standpoint. The perceived threat of future
antimicrobial resistance further compels eco-
nomical usage. Discontinuing ceftaroline fol-
lowing bacteremia resolution also potentially
eliminates several weeks of ceftaroline therapy.
In so doing, it allows for substantial cost savings
individually as well as institutionally.
No universal length-related definition of
prolonged MRSA bacteremia exists. We chose to
investigate patients administered ceftaroline
after at least 4 days of MRSA bacteremia given
said duration has been associated with an
increased risk of mortality [23]. This aside, there
were concerns that patient degree of comor-
bidities and/or illness severity influenced med-
ical providers’ decision to continue with
ceftaroline following bacteremia resolution.
Representative CCI and PBS values along with
subject ages were consequently used in
propensity score formulation. IPTW standard-
ization of the trial population was thereafter
implemented to diminish the likelihood of
indication bias compromising our findings.
Regarding study deaths, the occurrences
seemingly were not due to substandard
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antibiotic therapy. The one monotherapy
cohort patient likely instead expired from non-
infectious complications of valve surgery. As for
deaths in the combination therapy cohort, the
40-year-old male patient with native valve IE
likely expired from medically unpreventable/
untreatable disease sequelae given his pre-ex-
isting cerebral emboli. The 36-year-old female
patient with native valve IE likely expired from
a known consequence of critical illness—given
her fatal acute pulmonary embolism. Finally,
the 69-year-old male with both native valve IE
and osteomyelitis likely expired from an
unfortunate combination of disease severity
plus inadequate source control given the pro-
tracted duration of his preceding bacteremia.
However, evidence in support of these conclu-
sions is unable to be provided due to absent
autopsy results.
Our study is not without a few limitations.
Aside from the innate flaws associated with any
retrospective investigation, the study popula-
tion was admittedly modest. This was partly due
to infrequent episodes of prolonged MRSA bac-
teremia necessitating ceftaroline at our institu-
tion. Two stipulations additionally pared the
study census. A significant number of patients
were excluded from study consideration due to
absent accompanying osteomyelitis, native
valve IE, or brain abscess. These requirements,
though, were essential in ensuring subjects
appropriately received several weeks of antimi-
crobial therapy. It was feared that shorter
antibiotic courses could possibly obscure out-
come differences between the treatment groups.
Secondly, many patients were transferred from
neighboring medical centers with known MRSA
bacteremia. Limited accompanying medical
records/patient data precluded PBS score calcu-
lation. The subsequent inability to eliminate
severity of illness as a confounding factor war-
ranted their removal.
Another study limitation pertained to
patient deaths. As mentioned previously, three
subjects were removed from the study popula-
tion due to care being withdrawn during their
hospital stay. This was necessary in maintaining
study integrity. That being said, these patients
all had a minimal chance for recovery. Study
deaths may thus have been lessened by their
removal.
Although not a limitation per se, dapto-
mycin replaced vancomycin in several patients
once ceftaroline was begun. The change in
therapy was largely due to AKI or provider
preference. All involved MRSA isolates retained
vancomycin susceptibility at the time. In this
respect, the antibiotic change likely was incon-
sequential as both agents equally treat van-
comycin-susceptible MRSA bacteremia [4]. As
for the two combination therapy group patients
prescribed daptomycin due to emergent bor-
derline vancomycin-susceptible MRSA strains,
fears of vancomycin ineffectiveness led to the
substitution. Whether MIC creep absolutely
demands vancomycin discontinuation in
patients with MRSA bacteremia is unclear [26].
Regardless, the change in therapy likely did not
affect assessed patient outcomes. The fact that it
preceded bacteremia resolution and dapto-
mycin was continued (along with ceftaroline)
for 6–8 weeks as planned supports this
conclusion.
The PBS model was chosen for risk stratifi-
cation purposes as opposed to alternative scor-
ing systems due to it being developed expressly
for bacteremic subjects. The decision was fur-
ther supported by the studies of Gasch [24] and
Kim [25], which found PBS values greater than 3
to be associated with early mortality in patients
with MRSA bacteremia. This gave context to our
patients’ PBS values given that no universal
score interpretation exists. The median PBS
value of the combination therapy cohort was 2
and the median PBS value of the monotherapy
cohort was 1. As such, both treatment groups
lacked severely ill patients. This raises the
question of whether our findings apply to sicker
individuals. Also, the study population largely
consisted of middle-aged subjects with no past
medical history aside from intravenous drug
abuse. The absence of subjects with multiple
chronic medical problems led to a median CCI
score of 0 for both cohorts. This raises the
question of whether our findings apply to
individuals with considerable comorbid
conditions.
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CONCLUSION
In summary, discontinuing ceftaroline follow-
ing bacteremia resolution in patients with van-
comycin- or daptomycin-refractory complicated
and prolonged MRSA bacteremia resulted in no
statistically significant difference in treatment
outcomes versus patients who continued com-
bination therapy. This finding suggests restrict-
ing supplemental ceftaroline to bacteremic
patients. However, given the retrospective nat-
ure of our study and overall patient character-
istics, future prospective trials involving more
ill subjects with several chronic diseases would
be worthwhile.
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